Aktis Oncology Announces $175 Million Oversubscribed Series

Oct 1, 2024 · BOSTON, Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

CouponFollow Extension

$175
OFF

Aktis Oncology Announces $175 Million Oversubscribed Series

4 weeks from now

Oct 1, 2024 · BOSTON, Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

biospace.com

$175
OFF

Aktis Oncology Closes $175 Million Financing - Aktis

4 weeks from now

Oct 1, 2024 · The Pharma Letter

aktisoncology.com

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

BOSTON, Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

epicos.com

$175
OFF

Aktis Oncology Unveils $175M Series B Financing To Advance …

4 weeks from now

Sep 30, 2024 · By Karen Roman Aktis Oncology said it raised $175 million in Series B financing, led by RA Capital Management, with RTW Investments and Janus Henderson Investors as co …

yahoo.com

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

Sep 30, 2024 · Financing led by RA Capital Management and co-led by RTW Investments and Janus Henderson InvestorsProceeds to further advance the company's differentiated …

wpri.com

$175
OFF

Brown Rudnick Assists Aktis Oncology In $175M Series B Financing

4 weeks from now

Sep 30, 2024 · Brown Rudnick acted as corporate and transactional counsel for biotech company Aktis Oncology in its oversubscribed and upsized $175 million Series B financing. Aktis …

brownrudnick.com

$175
OFF

Aktis Oncology Announces $175 Million Oversubscribed Series B …

4 weeks from now

BOSTON, Sept. 30, 2024 -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad …

pappas-capital.com

$175
OFF

Series B - Aktis Oncology - 2024-09-30 - Crunchbase

4 weeks from now

Sep 30, 2024 · pr newswire — aktis oncology announces $175 million oversubscribed series b financing to further advance its proprietary radiopharmaceutical pipeline . news • sep 30, 2024. …

crunchbase.com

$175
OFF

Aktis Oncology Announces $175 Million Oversubscribed Series B …

4 weeks from now

BOSTON, Sept. 30, 2024 -- (Healthcare Sales & Marketing Network) -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted …

salesandmarketingnetwork.com

FAQs about Aktis Oncology Announces $175 Million Oversubscribed Series Coupon?

What happened to aktis oncology?

BOSTON, Mass. – September 30, 2024 — Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. ...

What is aktis oncology?

Aktis Oncology is a clinical stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors. The company’s first of several pipeline programs targets Nectin-4, a tumor-associated antigen found in urothelial and other solid cancers. ...

How much money does aktis oncology have?

The company now has more than $300 million in cash at its disposal, which it plans to use to test alpha radiopharmaceuticals against solid tumors. Aktis Oncology uses the radioisotope actinium-225 to develop radiopharmaceutical medicines for cancer. JacobH via Getty Images ...

When will aktis oncology present a presentation?

Aktis Oncology also announced that three abstracts, including one oral presentation, have been accepted for presentation at the upcoming in Barcelona, Spain, October 23-25, 2024. ...

Who will join the aktis Oncology board of directors?

In conjunction with the financing, Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management, will join the Aktis Oncology Board of Directors. Lauren Lee, PhD, from RTW Investments, and Vish Sridharan, MD, from Janus Henderson Investors, will join as Observers to the Board of Directors. ...

How does aktis oncology use actinium 225?

Aktis Oncology uses the radioisotope actinium-225 to develop radiopharmaceutical medicines for cancer. JacobH via Getty Images Boston-based Aktis Oncology has raised $175 million in fresh funding to advance its pipeline of radiopharmaceutical medicines for cancer. ...